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Abstract. Background/Aim: We examined the gene expression
changes of breast cancer cells spontaneously undergoing
epithelial–mesenchymal transition (EMT) and its reverse
process mesenchymal–epithelial transition (MET) and the role
of exosomes in these transitions. Materials and Methods:
Highly invasive mesenchymal-like breast cancer cells, 
MDA-MB-231 (basal cells), EMT and MET variants, were
characterized by microarray gene expression profiling, immuno -
cytochemistry and chemo-sensitivity. Results: Spontaneously
disseminated cells were anoikis resistant, exhibited a
dissociative, EMT-like phenotype and underwent MET when
reseeded in cell-free plates. MET was inhibited by exosomes
secreted by basal cells. Chemo-sensitivity to doxorubicin,
vincristine and paclitaxel decreased in the order
EMT<MET<basal. Phenotypic plasticity arose with differential
expression of metastasis and stemness associated genes (LGR5,
FZD10, DTX1, ErbB3, FTH1 and DLL4) and pathways (DNA
replication and repair, ABC transporter, Hedgehog, Notch and
metabolic pathways). Conclusion: This is an appropriate model
for studying EMT/MET transitions, drug targets and the role of
exosomes in breast cancer dissemination. 
Epithelial to mesenchymal transition (EMT) occurs during
tumor progression and contributes to cellular plasticity
endowing cancer cells with increased motility and
invasiveness (1, 2). A critical molecular feature of EMT is
the down-regulation of the adhesion molecule E-cadherin
and the acquisition of a mesenchymal phenotype associated
with the up-regulation of vimentin (3). When cancer cells
successfully establish metastasis at secondary sites, they
also undergo the reverse process known as
mesenchymal–to–epithelial transition (MET) and re-acquire
epithelial markers (4).
There are a number of experimental approaches able to
reproduce EMT in vitro such as the forced expression of
EMT-inducing transcription factors (5), transforming growth
factor-β (TGFβ) treatment (6) or transfection with C35 (7).
Trypsin-sensitive breast and colon cancer cells subpopulations
also showed characteristic of EMT (8). Similarly, EMT-like
phenotype can be increased by culturing cells on soft
substrates or on ultra-low attachment plates (9, 10). These
experimental manipulations artificially induced gene
expression alterations and cellular phenotypes, which may not
recapitulate the in vivo status of cells (11).
We have previously demonstrated that a subpopulation of
adherent colon cancer cells spontaneously undergoes EMT
and that this transition is stabilized by exosomes, since EMT
cells, in an exosomes depleted environment, undergo the
reverse process, MET (12). These findings demonstrate the
possibility to study the inter-conversion between epithelial
and mesenchymal states in vitro without any artificial
experimental manipulation and in the absence of exogenous
cues from the surrounding microenvironment. However,
since the degree of the ability to undergo EMT may differ
among tumors (13), in this study, we investigated whether
EMT and MET variants and their associated traits, such as
anoikis and therapy resistance, spontaneously emerge in the
highly invasive mesenchymal-like breast cancer cells MDA-
MB-231 and whether exosomes may be drivers of these
transitions. Moreover, although previous reports described
gene expression variation in experimentally induced EMT in
vitro (14-16), to our knowledge, none sought to identify the
dynamic gene expression changes leading to spontaneous
acquisition of EMT/MET phenotypes. 
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Materials and Methods
Cell culture and suspension cells. MDA-MB-231 cells were
maintained in DMEM (Invitrogen, Life technologies, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (Invitrogen),
100 U/ml penicillin-streptomycin, 1% l-glutamine (200 mmol/l),
4.5 g/l glucose and grown in 5% CO2. These cells are referred as
basal cells. After 7 days post seeding, a number of MDA-MB-231
cells able to survive in suspension appeared in the culture medium;
these cells that spontaneously found in suspension (referred as
EMT cells) were harvested by 500xg centrifugation for 5 min and
counted at different time points post seeding (48 h, 72 h, 96 h, 7
d, 10 d, 15 d). 
Exosomes isolation. Exosomes were isolated from MDA-MB-231
culture media at day 7 post-seeding by using the Exosome
Precipitation Solution (Macherey-Nagel, Düren, Germany). 
Adherent colonies formation. To test the ability of EMT cells to
form adherent colonies (referred as MET cells), 4×103 EMT cells
collected at day 7 were seeded in 24-well plates and maintained for
72 h in DMEM or in DMEM containing 10% or 20% of exosomes
isolated from basal cells culture media. MET cells were counted and
cell viability was measured by trypan blue (Invitrogen). 
Immunocytochemistry for E-cadherin and vimentin. Basal cells, as
well as EMT and MET variants, were seeded on histological slides,
fixed in 4% formaldehyde pH 7.4 for 10 min and pre-incubated in
0.5% triton and 1.5% bovine serum albumin (BSA) (Sigma Aldrich,
Milan, Italy) for 15 min at RT. Immunostaining was performed by
incubation for 24 h at 4˚C with mouse monoclonal anti E-cadherin
antibody at final dilution of 1:50 (Millipore, Burlington, MA, USA)
or goat-polyclonal anti-Vimentin antibody at final dilution 1:40
(Sigma Aldrich) followed by Alexa Fluor 488 Goat anti-mouse
(1:333) or Alexa Fluor 568 Donkey anti-Goat (1:333) antibodies
(Invitrogen). Microscopic analysis was performed with a
fluorescence microscope (Labophot-2, Nikon) connected to a CCD
camera. Ten photomicrographs (~100 cells/microscopic field) were
randomly taken for each sample and fluorescence was measured
using ImageJ 1.33 image analysis software (http://rsb.info.nih.gov/ij).
Results were expressed in arbitrary units.
Chemosensitivity assay. Differences in sensitivity among basal,
EMT and MET cells exposed to doxorubicin (10–6 M), paclitaxel
(10–6 M) or vincristine (10–6 M) for 72 h were assessed by MTS
assay (Promega Corporation, Madison, WI, USA). 
Reverse Transcription PCR. Total RNA was extracted by using the
RNeasy Mini kit Plus (Macherey-Nagel) according to the
manufacturer’s protocol. For first-strand cDNA synthesis, 1 μg of
total RNA from each sample was reverse-transcribed by using the
RevertAid RT Kit (Thermo Fisher Scientific, Waltham, MA, USA).
Primers were designed based on the human GenBank sequences.
For each target gene, the relative amount of mRNA in the samples
was calculated as the ratio of each gene to GAPDH mRNA (17).
Microarray experiments. To produce Cy3- labeled complementary
RNA (cRNA), 550 ng of total RNA from the three cell clones, were
labeled using the Agilent Quick Amp Labeling Kit (Agilent
Technologies, Santa Clara, CA, USA) following the manufacturer’s
protocol. The Cy3-labeled samples were hybridized to Agilent
Whole human genome 4X44K microarrays at 65˚C for 18 h.
Fluorescent signal intensities were detected using the Agilent Scan
Control 7.0 Software on an Agilent DNA Microarray Scanner, at a
resolution of 2 μm. Microarray analysis was performed on 3
independent biological replicates for each cell clone. Image
analysis and initial quality control were performed using Agilent
Feature Extraction Software v9.5. Values for control spots and
spots that did not meet the quality criteria were flagged. Quality
criteria included a minimal spot size, a median/mean ratio of at
least 0.9 for each spot, non-saturated intensity for both channels, a
signal well above background and a minimal signal intensity for at
least one channel. Initial statistical analysis was performed using
unpaired t-test considering Benjamini–Hochberg corrected p-value
of 0.05. BRB-Array Tools 4.5.1 version was used to perform
Statistical Analysis of Microarray (SAM), Gene set enrichment
analysis (GSEA) and a two-way hierarchical clustering. Microarray
data are stored into the Array Express database with accession
number E-MTAB-6954.
Statistical analysis. Data were expressed as means±SEM of three
independent experiments. Statistical analysis was performed by one-
way analysis of variance, followed by the Student–Newman–Keuls
multiple comparison post hoc test or by Mann–Whitney test.
Calculations were done using a GraphPad Prism 4.0 (GraphPad
software, San Diego, CA, USA).
Results 
Behavioral characterization of suspension EMT cells and
effect of exosomes secreted by basal cells on the reverse
transition from EMT to MET. At 48 h post-seeding, a
subpopulation of MDA-MB-231 basal cells detached the
monolayer and spontaneously disseminated in the culture
media. The number of cells growing in suspension
significantly increased from the seventh to the fifteenth day
post-seeding suggesting anoikis resistance and EMT like
features (Figure 1A). When 4×103 suspension cells were
collected and re-seeded in cell-free wells, they were able to
adhere again and to form about 300 new adherent viable
colonies suggesting the occurrence of MET.
When exosomes isolated from the culture medium of basal
cells were added at a concentration of 10% or 20% to EMT
cells, their ability to undergo MET in cell-free wells was
significantly and dose dependently reduced compared to
DMEM alone (Figure 1B).
Expression of the EMT hallmarks vimentin and E-cadherin.
Adherent MDA-MB-231 cells (Basal), had high expression
levels of E-cadherin and low expression of vimentin (Figure
2A and B). On the contrary, disseminated MDA-MB-231
(EMT) were E-cadherin low and vimentin high (Figure 2C
and D). When the latter where re-seeded in cell-free wells,
they reverted back to the epithelial state forming new
adherent viable colonies (MET), that were E-cadherin high
and vimentin low (Figure 2E and F); Figure 2G and H show
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the results of the densitometric analysis of E-cadherin and
vimentin, respectively, in basal, EMT and MET cells. The
gene expression of vimentin and E-cadherin recapitulated the
results of immunocytochemistry with EMT cells displaying
up-regulation of vimentin and down-regulation of E-cadherin
compared to both adherent and MET cells (Table I).
Chemosensitivity assay. In basal cells, the percentage of cell
death was of 28 %, 38 % and 42% upon doxorubicin,
paclitaxel and vincristine treatment, respectively. These
percentages were dramatically reduced in EMT cells which
were almost insensitive to all the three chemotherapeutic
agents with percentages of cell death below 10 %
(p<0.001). The chemosensitivity to doxorubicin was
completely restored in MET cells whereas that to paclitaxel
and vincristine was only partially reacquired compared to
basal cells (Figure 3).  
Whole-gene expression analysis and Gene Set Enrichment
Analysis (GSEA). Transcriptomic analysis identified 223
differentially expressed genes between EMT cells and
basal cells; among the genes that were up-regulated in
EMT compared to basal cells are DTX1, ADH1A, BCAS1,
FZD10 and ERBB3; beta 1 catenin (CTNNB1) was instead
down-regulated. 219 genes were found differentially
expressed by comparing EMT and MET cells: FTH1, was
up-regulated in EMT compared to MET cells whereas
DLL4 was down-regulated. PBOV, BMP7, RHOJ, ELA2B
and ELA3B were all up-regulated in MET, and were among
the 319 differentially expressed genes between MET and
basal cells.
Unsupervised hierarchical clustering analysis was
performed in order to evaluate the degree of changes in gene
expression observed in EMT and MET cells compared to
basal cells. The results are shown in the form of a tree whose
branch lengths reflect the degree of similarities among the
experimental groups; thus, similar expression profiles are
closer to each other. This analysis distinguished the
expression profiles of the three cell clones and in particular
those of EMT cells compared to basal cells (Figure 4A).
Venn diagrams showed the degree of overlapping results
in gene expression among different comparisons (Figure 4B).
In particular, the expression of a single gene, the heath shock
protein HSP90AA, emerged from all the three comparisons
and was up-regulated in basal and EMT cells compared to
MET. Interestingly, 7 genes whose expression regulation
emerged from the comparison between basal and EMT and
between EMT and MET were found. LGR5, SLC30A2 and
COBL were overexpressed in EMT cells compared to basal
and MET. Instead, CYTB, ADH5, ARL13B and ATP5B were
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Figure 1. Behavioral characterization of suspension EMT cells and effect of exosomes secreted by basal cells on the reverse transition from EMT
to MET. A: Time-dependent increase in the number of viable MDA-MB-231 cells spontaneously growing in suspension. Data are expressed as
means±SEM of 3 independent experiments. ***p<0.001 vs. 48 h. B: Number of adherent new colonies (MET cells) formed by EMT cells in DMEM
alone or in the presence of 10% and 20% exosomes isolated from the culture medium of basal cells.  ***p<0.001 vs. DMEM alone.
Table I. Expression of vimentin and E-cadherin, in basal, EMT and
MET.
Gene                             Basal                        EMT                         MET
Vimentin                   0.39±0.03              0.78±0.05**             0.31±0.02##
E-Cadherin               0.43±0.04                   ND**                  0.22±0.01#
Data are expressed as mean±SEM of the relative amount of each gene
vs. the housekeeping gene, GAPDH. *p<0.05, **p<0.01 vs. Basal;
#p<0.05, ##p<0.01 vs. EMT. 
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Figure 2. Continued
highly expressed in basal and MET compared to EMT. When
comparing MET cells to EMT and basal cells, 26 genes were
differentially expressed: PBOV1 was up-regulated in EMT
and MET cells compared to basal cells, FTH1 and SIRT3
were up-regulated in basal and EMT compared to MET cells,
and ELA3B was up-regulated in MET compared to basal and
EMT cells.
In order to evaluate the biological processes characterizing
the three cell clones, a Gene Set Enrichment Analysis
(GSEA) was performed. This analysis measures the
cumulative effect of small but consistent changes in gene
expression within a biological pathway. Forty-six out of 136
KEGG pathways passed the 0.001 significance threshold.
Table II shows the first 22 gene sets of the list. Among them,
genes associated to the DNA replication (hsa03030), base
excision repair (hsa03410) and TCA cycle (hsa00020) were
mainly up-regulated in MET compared to basal and EMT
cells (Figure 5). Other gene sets significantly enriched in
EMT and MET cells were mTOR, NOD-like receptor
signaling and several metabolic pathways.
Moreover, comparing each cell variant to the other ones,
the Hedgehog signaling pathway found to be down-regulated
in basal cells, became up-regulated in EMT and returned to
a down-regulated state in MET. ABC transporters were
mostly up-regulated in MET cells, drug metabolism-
associated genes were overall down-regulated in basal cells,
whereas both EMT and MET showed an up-regulation of
this gene set. Notch was up-regulated in EMT cells
compared to both basal and MET cells (Figure 6).
GSEA identified also 48 gene sets, computationally predicted
to be targets of the same miRNA, that were differentially
expressed in EMT, MET and basal cells (Table III). As an
example, Figure 7, shows the heat maps with the list of genes
predicted to be targets of miR-30b, miR-181a, and miR134.
Discussion
Metastasis is the major cause of treatment failure and death
in breast cancer patients (18). For many years, EMT has
been seen as an extreme phenotype, recapitulated in vitro
with artificial manipulations which keep cells in a fixed
state. However, there is evidence that, in vivo, cancer cells
undergo a spectrum of intermediate states called metastable
phenotypes in which cells retain some epithelial features but
also acquire mesenchymal characteristics (19). These hybrid
phenotypes that seem to be facilitated in collective cell
migration, are associated with the acquisition of stem-like
properties, chemoresistance and aggressiveness (20-21).
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Figure 2. Expression of the EMT hallmarks vimentin and E-cadherin. Immunocytochemical evaluation of the expression of E-cadherin (A) and
vimentin (B) in adherently growing MDA-MB-231 cells (Basal). Expression of E-cadherin (C) and vimentin (D) in MDA-MB-231 growing in
suspension (EMT). Expression of E-cadherin (E) and vimentin (F) in adherent new colonies (MET) obtained by seeding disseminated MDA-MB-
231 cells in cell-free wells (20x magnification; Barr 100 mm objective). Densitometric analysis of E-cadherin in Basal, EMT and MET cells (G).
Densitometric analysis of vimentin in Basal, EMT and MET cells. **p<0.01 vs. Basal and MET cells (H).
Figure 3. Chemosensitivity assay in basal, EMT and MET cells. Data
are expressed as means±SEM of 3 independent experiments.
***p<0.001 vs. adherent MDA-MB-231.
These observations illustrate the importance of studying
EMT in a non-experimentally manipulated setting (11).
Moreover, most of the in vitro studies conducted so far,
focused on EMT transition rather to its reverse process MET.
Park et al. recently demonstrated that a long-term suspension
of MDA-MB-468 cells resembled some features of human
circulating tumor cells (10), but did not investigate their
ability to overcome the EMT program, which is essential for
metastatic colonization. 
In line with our previous results on HCT8 colon cancer
cells, we demonstrated that EMT transition spontaneously
occurs also in MDA-MB-231 cells, and that exosomes
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Table II. Top 22 KEGG gene sets found to be differentially modulated by comparing basal, EMT and MET cells.
Kegg Pathway                                          Pathway description                                          Number of             LS permutation             KS permutation 
                                                                                                                                                 genes                         p-Value                           p-Value
hsa05219                                                       Bladder cancer                                                      65                          0.00001                           0.00005 
hsa05221                                               Acute myeloid leukemia                                              96                          0.00003                           0.00001 
hsa04150                                              mTOR signaling pathway                                             83                          0.00005                           0.00014 
hsa05120                     Epithelial cell signaling in Helicobacter pylori infection                    98                          0.00008                           0.00001 
hsa05223                                             Non-small cell lung cancer                                            82                          0.00008                           0.00015 
hsa03030                                                      DNA replication                                                     47                          0.00009                           0.00001 
hsa04621                                    NOD-like receptor signaling pathway                                   79                          0.00011                           0.00011 
hsa05213                                                   Endometrial cancer                                                  87                          0.00017                           0.0018
hsa00310                                                    Lysine degradation                                                   78                          0.00032                           0.00136
hsa05130                                     Pathogenic Escherichia coli infection                                   91                          0.00077                           0.00002 
hsa03008                                      Ribosome biogenesis in eukaryotes                                     98                          0.00083                           0.00001 
hsa00450                                          Seleno compound metabolism                                         22                          0.00089                           0.00094 
hsa03410                                                   Base excision repair                                                  54                          0.00159                           0.00001 
hsa05214                                                             Glioma                                                          100                          0.00168                           0.00082 
hsa00020                                              Citrate cycle (TCA cycle)                                             48                          0.00209                           0.00047 
hsa03022                                              Basal transcription factors                                             49                          0.00224                           0.00001 
hsa04962                                 Vasopressin-regulated water reabsorption                                78                          0.0025                              0.00024 
hsa00330                                        Arginine and proline metabolism                                       76                          0.00638                           0.00035 
hsa00520                             Amino sugar and nucleotide sugar metabolism                            65                          0.00704                           0.00097 
hsa00630                                 Glyoxylate and dicarboxylate metabolism                                27                          0.01191                            0.00069 
hsa04146                                                          Peroxisome                                                         98                          0.01792                           0.00002 
hsa00280                                Valine, leucine and isoleucine degradation                               68                          0.02396                           0.00039 
Figure 4. Gene Expression Analysis. A: Hierarchical clustering of gene expression profiles of EMT, MET and basal cells. B: Venn diagram showing
the number of differentially expressed genes in the three cell clones, the degree of overlap between the differentially expressed genes in the three
comparisons; non-overlapping numbers specify the genes unique to each comparison. 
stabilize the EMT phenotype allowing anoikis resistance;
when exosomes are removed, EMT cells revert back to the
epithelial state, undergoing MET. In vivo, it is likely that a
complex mix of signals, both from cancer cells and from the
tumor microenvironment, contribute to these transitions: in
the elegant paper from Chao and coworkers, MDA-MB-231
exhibited a reversion to an epithelial phenotype when
cultured with hepatocytes, suggesting that micro
environmental factors may modulate this switch (22).
However, our results suggest that at least part of the plasticity
of the EMT and MET phenotypes can be driven by exosomes,
reinforcing the idea that by secreting exosomes, primary
cancer cells try to preserve their own niche meanwhile
endowing cells with migratory and invasive traits necessary
to colonize other free niches (12). 
In addition, EMT cells are selectively advantaged through
the acquisition of chemoresistance to doxorubicin, vincristine
and paclitaxel, the most commonly used drugs for the
therapy of breast cancer. Interestingly, upon the acquisition
of the MET phenotype, the sensitivity to doxorubicin is
completely re-acquired and that of vincristine and paclitaxel
is significantly regained, but still reduced compared to
parental cells.
Whole gene expression analysis showed that EMT and
MET cells are molecularly distinct variants compared to
adherent cells. Given the large number of genes
differentially expressed, attention was paid on those
expressed in an opposite manner almost in two out of the
three cell clones, as it was hypothesized that metastasis-
related genes are more likely to be oppositely expressed. A
number of genes associated with metastatic activity and
cancer stem cell traits were identified. Among those are the
leucine-rich repeat-containing G-protein-coupled receptor
5 (LGR5), a stem cell marker in intestinal crypts and
mammary glands (23) that promotes cell mobility, tumor
formation and EMT in breast cancer cells by activating
Wnt/β-catenin signaling (24), FZD10, a receptor for Wnt
signalling, that is up-regulated in breast cancer and is a
potential drug target (25), DTX1, a Notch interacting
protein that is also associated with the proliferative,
migratory and clonogenic potential of cancer cells (26) and
elevated expression of ErbB3 resulting in paclitaxel
resistance in breast cancer cells (27).
Among the most up-regulated genes in EMT cells
compared to MET cells, was the FTH1 gene, a subunit of the
ferritin complex, which is associated with the progression of
breast cancer and with increased resistance to doxorubicin
(28). DLL4 (Delta-like 4), a component of the Notch
signaling pathway, has also been implicated in EMT and
chemoresistance (29).
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Table III. Top 22 gene sets computationally predicted to be targets of the same miRNA, found to be differentially modulated by comparing basal,
EMT and MET cells.
                    MicroRNA GeneSets                      Number of                LS permutation               KS permutation              Efron-Tibshirani’s GSA test 
                                                                                 genes                           p-Value                             p-Value                                      p-Value
1                       hsa-miR-30d-5p                                 12                              0.00001                           0.00009                                      0.055 
2                       hsa-miR-424-5p                                 37                              0.00001                           0.00254                                       0.285 
3                      hsa-miR-133a-3p                                39                              0.00001                           0.00063                                      0.285 
4                       hsa-miR-503-5p                                 23                              0.00004                           0.00284                                     <0.005 
5                        hsa-miR-24-3p                                  61                              0.00006                           0.00048                                      0.345 
6                       hsa-miR-221-3p                                 52                              0.00007                           0.00005                                      0.195 
7                      hsa-miR-181a-5p                                44                              0.00009                           0.00003                                      0.215 
8                       hsa-miR-26a-5p                                 56                              0.00009                           0.00015                                      0.255 
9                       hsa-miR-134-5p                                   6                              0.00011                           0.00498                                       0.105 
10                    hsa-miR-199a-5p                                23                              0.00013                           0.0021                                         0.055 
11                     hsa-miR-143-3p                                 27                              0.00015                           0.00001                                      0.3 
12                     hsa-miR-183-5p                                 13                              0.00015                           0.00306                                       0.11 
13                     hsa-miR-141-3p                                 63                              0.0002                             0.00177                                       0.605 
14                     hsa-miR-15a-5p                                 36                              0.00028                           0.04089                                       0.275 
15                     hsa-miR-222-3p                                 35                              0.00033                           0.00154                                       0.19 
16                    hsa-miR-200a-3p                                46                              0.00058                           0.01587                                       0.25 
17                        hsa-miR-661                                     9                              0.00082                           0.00084                                      0.335 
18                      hsa-miR-25-3p                                  18                              0.00085                           0.00384                                       0.195 
19                    hsa-miR-193b-3p                                21                              0.00089                           0.01751                                       0.29 
20                      hsa-miR-16-5p                                  40                              0.0009                             0.02266                                       0.545 
21                        hsa-let-7c-5p                                   16                              0.00092                           0.00048                                      0.025 
22                     hsa-miR-127-3p                                   8                              0.001                               0.00298                                       0.18 
The unique gene significantly modulated in the three cell
variants was HSP90AA1, a member of the HSP90 family
whose expression is an independent risk factor of death from
metastatic breast cancer in TNBC (30) and it is associated to
chemoresistance (31). Pharmacological inhibitors of HSP90
in breast cancer treatment are under investigation in clinical
trials (32).
An alternative approach to the analysis of single gene
expression variations, is GSEA analysis, where a group of
related genes from the same pathway is examined instead of
groups of potentially unrelated genes. This approach has the
advantage of taking into account the cooperative nature of
genes and of considering that genes involved in the same
process are often regulated together. Among the gene sets
found to be differentially expressed among the three cell
variants the DNA replication end Base Excision Repair was
found; most of the genes listed in these pathways were in fact
up-regulated in MET cells, suggesting that both mechanisms
might be involved in cell survival and chemoresistance after
re-adhesion. TCA cycle, mTOR, NOD-like receptor signaling
and several metabolic gene sets were also enriched in EMT and
MET cells. Hedgehog signaling pathways were clearly down-
regulated in basal cells, became up-regulated in EMT cells and
returned to a down-regulated state in MET cells. A similar
trend was observed for Notch pathway; interestingly, both
contribute to the maintenance of stem-like properties and favor
chemoresistance and metastasis (33). ABC transporters and
drug metabolism pathways were activated in MET cells and in
both EMT and MET cells respectively, suggesting their
potential role in the acquisition of chemoresistance. GSEA also
identified several gene sets predicted to be targets of the same
miRNA; the most differentially expressed gene set was that
associate with the miR-30d recently recognized as a mediator
of invasion, migration and EMT in breast cancer (34).
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Figure 5. Heat maps representing the three KEGG pathways pointed out by Gene Set Enrichment Analysis (GSEA) of MDA-MB-231 cells
transcriptomic data: DNA replication (hsa03030), base excision repair (hsa03410) and TCA cycle (hsa00020). Up-regulated genes are shown in
dark blue, down-regulated genes in light blue color. 
In conclusion, evidence was provided indicating that a
dynamic gene expression reprogramming during EMT-MET
takes place in vitro without any experimental manipulation
and that it is associated to the acquisition of chemoresistance
and metastatic traits. This model is useful for studying EMT
and MET transitions, drug targets and the role of tumor-
derived exosomes in breast cancer.  
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